INTRODUCTION

6
while it was the predominant causative in 5 other studies.(9, 13, 17, 20, 23) In one 160 study, the major causative pathogen was Enterobacter cloacae. (27) In 8 In seven studies, the 28-or 30-day mortality was provided, (10, 13, 17-19, 25, 27) in 168 one the 14-day mortality,(12) in four studies the in-hospital mortality,(9, 11, 15, 16) in 169 two the overall mortality,(22, 23) in one the infection-related mortality,(28) and in 170 three the type of mortality provided was not determined. studies was recorded. Due to the fact that some treatment regimens were administered 178 to very few patients in certain studies, only regimens reporting on more than 3 179 patients from each study were taken into account. 180
181
With regard to patients who received combination treatment, mortality varied from 182 0% to 30% among 51 patients (4 studies)(10, 11, 25, 28) who received the 183 tigecycline-colistin combination, from 0% to 50% among 15 patients (2 studies) (25, 184 28) who received the tigecycline-gentamicin combination, from 0% to 67% for 25 185 patients (4 studies)(12, 19, 22, 23) treated with carbapenem-colistin combination, and 186 from 40% to 61% for 30 patients (3 studies)(11, 16, 25) treated with colistin-187 gentamicin combination. In a study including only intensive care unit (ICU)-patients, 188 the 11 patients with infections due to VIM-1-producing isolates who were treated with 189 the tigecycline-colistin combination had 64% mortality. 
